MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026
Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics, today announced updated clinical findings from patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with its lead investigational product candidate, ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE), following presentation at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
The 81-patient experience represents one of the largest clinical datasets reported to date for an albumin-binding peptide receptor radionuclide therapy (PRRT) and provides growing evidence that EBTATE may offer a differentiated and potentially best-in-class profile compared with conventional PRRT approaches.
Key Clinical Highlights from 81 Treated GEP-NET Patients
Approximately 8-fold higher tumor uptake compared with conventional PRRT
